A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection

Expert Opinion on Investigational Drugs

Volumn 21, Issue 5, 2012, Pages 695-715

  Gengiah, Tanuja N ^a   Baxter, Cheryl ^a   Mansoor, Leila E ^a   Kharsany, Ayesha B M ^a   Abdool Karim, Salim S ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Department of Medicine   (United States)

Author keywords

ART; HIV prevention; Microbicide; NtRTI; PMPA 9 R (2 Phosphonomethoxypropyl) adenine ; Tenofovir; Tenofovir disoproxil fumarate

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; CIDOFOVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GS 7340; MTN 007; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ARTICLE; COITUS; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EPIDEMIC; GASTROINTESTINAL DISEASE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SYSTEMIC THERAPY; TABLET FORMULATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION;

ADENINE; ANIMALS; ANTI-HIV AGENTS; GELS; HIV INFECTIONS; HUMANS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TABLETS;

EID: 84859726964     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.667072     Document Type: Article

References (103)

1. Buchbinder SP. HIV epidemiology and breakthroughs in prevention 30 years into the AIDS epidemic. Top Antivir Med 2011;19(2):38-46
2. UNAIDS. UNAIDS World AIDS Day Report 2011. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/ 2011/JC2216-WorldAIDSday-report-2011-en.pdf [Accessed 24 November 2011] Geneva: Joint United Nations Programme on HIV/AIDS; 2011
3. Leclerc-Madlala S. Age-disparate and intergenerational sex in southern Africa: the dynamics of hypervulnerability. AIDS 2008;22(Suppl 4):S17-25
4. Abdool Karim Q, Kharsany AB, Frohlich JA, et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 2011;12:67
5. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354(9181):795-802 (Pubitemid 29415583)
6. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011;11(3):171-80
7. Young TN, Arens FJ, Kennedy GE, et al. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev 2007(1):CD002835
8. Padian NS, McCoy SI, Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet 2011;378(9787):269-78
9. Kelly CG, Shattock RJ. Specific Microbicides in the Prevention of HIV Infection. J Intern Med 2011;270(6):509-19
10. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987;8(5-6):261-72 (Pubitemid 18073222)
11. Bronson JJ, Kim CU, Ghazzouli I, et al. Synthesis and antiviral activity of phosphonylmethoxyethyl derivatives of purine and pyrimidine bases. In: Martin JC, editor. ACS Symposium Series 401: Nucleosite Analogues as Antiviral Agents; 1989. American Chemical Society; Washington, DC: 1989. p. 72-87
12. Partners PrEP Study. Press Release: Pivotal Study finds that HIV Medications are Highly Effective as Prophylaxis Against HIV Infection in Men and Women in Africa. 2011. Available from: http://depts.washington. edu/astda/resources/PrEP-PressRelease-UW-13Jul2011.pdf [Cited 15 November 2011]
13. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363(27):2587-99
14. Thigpen MKP, Smith D, Segolodi T, et al. Daily Oral Antiretroviral use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana: Results from the TDF2 Study. IAS; Rome: 2011
15. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168-74
16. De Clercq E, Descamps J, De Somer P, Holy A, (S)-9-(2,3-Dihydroxypropyl) adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 1978;200(4341):563-5 (Pubitemid 8328394)
17. De Clercq E, Holy A, Rosenberg I, et al. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323(6087):464-7. (Pubitemid 16026278)
18. De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 2007;75(1):1-13 (Pubitemid 46610520)
19. Elion GB. Acyclovir: discovery, mechanism of action, and selectivity. J Med Virol 1993(Suppl 1):2-6 (Pubitemid 23290476)
20. Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977;74(12):5716-20
21. Votruba I, Holy A, De Clercq E. Metabolism of the broad-spectrum antiviral agent, 9-(S)-(2,3-dihydroxypropyl) adenine, in different cell lines. Acta Virol 1983;27(3):273-6 (Pubitemid 13098737)
22. De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol 2007;73(7):911-22
23. De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005;4(11):928-40. (Pubitemid 41637695)
24. Balzarini J, Holy A, Jindrich J, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 1993;37(2):332-8 (Pubitemid 23046579)
25. Balzarini J, Aquaro S, Perno CF, et al. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6- diaminopurine against human immunodeficiency virus in different human cell systems. Biochem Biophys Res Commun 1996;219(2):337-41 (Pubitemid 26090906)
26. Maudgal PC, De Clercq E, Huyghe P. Efficacy of (S)-HPMPA against thymidine kinase-deficient herpes simplex virus-keratitis. Invest Ophthalmol Vis Sci 1987;28(2):243-8 (Pubitemid 17015747)
27. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995;270(5239):1197-9
28. Van Rompay KK, Berardi CJ, Aguirre NL, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 1998;12(9):F79-83 (Pubitemid 28276961)
29. Van Rompay KK, Marthas ML, Lifson JD, et al. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses 1998;14(9):761-73 (Pubitemid 28265737)
30. Van Rompay KK, Miller MD, Marthas ML, et al. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 2000;74(4):1767-74 (Pubitemid 30434034)
31. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72(5):4265-73 (Pubitemid 28188732)
32. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000;74(20):9771-5
33. CONRAD. Investigators Brochure: Tenofovir Gel (GS-1278). CONRAD; Arlington, Virgina: 2010
34. Parikh UM, Dobard C, Sharma S, et al. Complete protection from repeated vaginal SHIV exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009;83(20):10358-65
35. Miller C, Rosenberg Z, Bischofberger N. Use of topical PMPA to prevent vaginal transmission of SIV. 9th International Conference on Antiviral Research; Japan; 1996
36. Van Rompay KK, McChesney MB, Aguirre NL, et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis 2001;184(4):429-38 (Pubitemid 32718506)
37. Dobard C, Sharma S, Martin A, et al. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 2012;86(2):718-25
38. Cranage M, Sharpe S, Herrera C, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008;5(8):e157
39. Van Rompay KK, Schmidt KA, Lawson JR, et al. Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus. J Infect Dis 2002;186(10):1508-13 (Pubitemid 35286123)
40. Van Rompay KK, Kearney BP, Sexton JJ, et al. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr 2006;43(1):6-14 (Pubitemid 44306481)
41. Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006;194(7):904-11 (Pubitemid 44454075)
42. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008;5(2):e28
43. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010;2(14):14ra4
44. Garcia-Lerma JG, Aung W, Cong ME, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol 2011;85(13):6610-17
45. Malcolm RK, Edwards KL, Kiser P, et al. Advances in microbicide vaginal rings. Antiviral Res 2010;88(Suppl 1):S30-9
46. Moss JA, Baum MM, Malone AM, et al. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. AIDS 2012; [Epub ahead of print]
47. Moss JA, Malone AM, Smith TJ, et al. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother 2012;56(2):875-82
48. Johnson TJ, Gupta KM, Fabian J, et al. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 2010;39(4):203-12
49. AVAC: Global Advvocacy for HIV Prevention. Table: Ongoing and Planned Clinical Trials of Topical Microbicide Candidates, January 2012. 2012. Available from: http://www.avac.org/ht/a/GetDocumentAction/i/3109 [Cited 8 February 2012]
50. Gilead Sciences, Inc. Full prescribing information: Viread. 2011 September 2011. Available from: http://rsc.tech-res. com/ safetyandpharmacovigilance/PIList.aspx
51. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43(9):595-612 (Pubitemid 38951802)
52. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis. AIDS 2007;21(14):1899-907 (Pubitemid 47329766)
53. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:112re4
54. Schwartz JL, Rountree W, Kashuba AD, et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011;6(10):e25974
55. Hendrix C MA, Guddera V, Riddler S, et al. MTN-001: A Phase 2 Cross-over Study of Daily Oral and Vaginal TFV in Healthy, Sexually Active Women Results in Significantly Different Product Acceptability and Vaginal Tissue Drug Concentrations [abstract#: 35LB]. 18th Conference on Opportunistic Infections and Retroviruses; 27 Februery 2011-22 March 2011; Boston, MA, USA; 2011.
56. Abdool Karim SS, Kashuba A, Werner L, Abdool Karim Q, Drug concentrations following topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011;378:279-81
57. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006;20(4):543-51 (Pubitemid 43731598)
58. Rosen RK, Morrow KM, Carballo-Dieguez A, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health (Larchmt) 2008;17(3):383-92 (Pubitemid 351457833)
59. Schwartz JL, Poindexter A, Wheeless A, et al. Safety evaluation of 1% tenofovir gel in healthy men. Int J STD AIDS 2009;20(6):384-6.
60. ClinicalTrials.gov. A04-095: Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel 2007. Available from: http://clinicaltrials. gov/ct2/show/NCT00561496 [Cited 22 September 2011]
61. Keller MJ, Madan RP, Torres NM, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 2011;6(1):e16475.
62. MicrobicideTrials Network. MTN 002: Phase I Study of the Maternal Single-Dose Pharmacokinetics and Placental Transfer of Tenofovir 1% Vaginal Gel among Healthy Term Gravidas 2011. Available from: http://www.mtnstopshiv.org/ news/studies/mtn002 [Cited 14 November 2011]
63. Microbicide Trials Network. Press Release: Researchers report results of first microbicide trial in pregnant women. Study indicates small amount of drug passes to fetus. Available from: http://www.mtnstopshiv.org/node/1846 [Cited 15 November 2011]
64. Anton P, Cranston R, Carballo-Dieguez A, et al. RMP-02/MTN-006: A Phase 1 Placebo-controlled Trial of Rectally Applied 1% Vaginal TFV Gel with Comparison to Oral TDF. 18th Conference in Retroviruses and Opportunistic Infections; 27 February 2011-22 March 2011; Boston, MA, USA; 2011.
65. MicrobicideTrials Network. MTN 007: A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel. 2011. Available from: http://www. mtnstopshiv.org/node/912 [Cited 11 November 2011]
66. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010;5(2):e9310.
67. MicrobicideTrials Network. MTN 008: Expanded Safety of Tenofovir 1% Gel in Pregnancy and Lactation. 2011. Available from: http://www.mtnstopshiv.org/ node/1637 [Cited 10 November 2011]
68. ClinicalTrials.gov. A10-113: Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel. 2011. Available from: http://clinicaltrials.gov/ct2/show/ NCT01369303?term=A10-113&rank=1 [Cited 22 September 2011]
69. Microbicide Trials Network. MTN 006: Phase 1 rectal microbicide safety and acceptability trial of topically applied tenofovir compared with oral tablet. Available from: http://www.mtnstopshiv. org/node/911 [Cited 14 November 2011]
70. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007;2(5):e27.
71. ClinicalTrials.gov. CDC 4323: Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men. Available from: http://clinicaltrials.gov/ct2/show/NCT00131677?term=CDC+4323 &rank=1 [Cited 15 November 2011]
72. Centers for Disease Control and Prevention. Preliminary Results from First Safety Study of Daily Tenofovir for HIV Prevention Among MSM Find No Significant Concerns. 2010. Available from: http://www.cdc.gov/hiv/prep/ resources/factsheets/extended-PrEBsafety-trial.htm [Cited 15 November 2011]
73. Ramjee G, Doncel GF, Mehendale S, et al. Microbicides 2008 conference: from discovery to advocacy. AIDS Res Ther 2008;5:19
74. Hillier SL. Safety and Acceptability of Coitally Dependent use of 1% Tenofovir Over Six Months of use. Abstract No. 655 Microbicides; New Delhi, India: 2008
75. Abdool Karim Q. on behalf of the CAPRISA 004 Trial Group. CAPRISA 004: effectiveness and safety of vaginal microbicide 1% tenofovir gel for prevention of HIV infection in women. Session TUSS05. Program and abstracts of the 18th International AIDS Conference; 18-23 July 2010; Vienna, Austria; 2010
76. Microbicide Trials Network. MTN 001: Phase 2 Adherence and Pharmacokinetics Study of Oral and Vaginal Preparations of Tenofovir. Available from: http://www.mtnstopshiv.org/node/71 [Cited 15 November 2011]
77. Hendrix C MA, Guddera V, Riddler S, et al. MTN-001: A Phase II Cross-over Study of Daily Oral and Vaginal TFV in Healthy, Sexually Active Women Results in Significantly Different Product Acceptability and Vaginal Tissue Drug Concentrations. CROI; Boston; 2011.
78. Microbicide Trials Network. MTN 003: Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disoproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women. Available from: http://www.mtnstopshiv.org/node/70 [Cited 15 November 2011]
79. Microbicide Trials Network. Questions and Answers on Decision to Modify VOICE. Available from: http://www. mtnstopshiv.org/node/3622 [Cited 15 November 2011]
80. Microbicide Trials Network. MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women. Available from: http://www.mtnstopshiv. org/node/3909 [Cited 25 November 2011]
81. National institute of allergy and infectious diseases. NIH Discontinues Tenofovir Vaginal Gel in 'VOICE' HIV Prevention Study. 2011. Available from: http://www.niaid.nih.gov/news/newsreleases/2011/Pages/VOICEdiscontinued.aspx [Cited 25 November 2011]
82. ClinicalTrials.gov. PartnersPrEP: Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples. Available from: http://clinicaltrials.gov/ct2/show/NCT00557245? term=PartnersPrEP&rank=1 [Cited 22 September 2011]
83. Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 2011;15(Suppl 1):S72-9
84. Partners PrEP study press release. Pivotal study finds that HIV medications are highly effective as prophyalxis against HIV infection in men and women in Africa. 2011. Available from: http://depts.washington.edu/uwicrc/ research/studies/files/PrEP-PressRelease-UW-13Jul2011.pdf [Cited 13 July 2011]
85. ClinicalTrials.gov. CDC 4370: Bangkok Tenofovir Study. Available from: http://clinicaltrials.gov/ct2/show/NCT00119106?term=cdc+4370&rank=1 [Cited 22 September 2011]
86. Martin M, Vanichseni S, Suntharasamai P, et al. Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS ONE 2011;6(9):e25127
87. ClinicalTrials.gov. FACTS 001: Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Young Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection. Available from: http://clinicaltrials.gov/ct2/show/ NCT01386294?term=facts+001&rank=1 [Cited 09 November 2011]
88. ClinicalTrials.gov. MTN 003B: Bone Mineral Density Substudy-An Ancillary Study to MTN-003. Available from: http://clinicaltrials.gov/ct2/show/ NCT00729573?term=mtn003b&rank=1 [Cited 15 November 2011]
89. Microbicide Trials Network. MTN 003C: Household and Community Level Factors Associated with Study Product Adherence in VOICE: A Substudy of MTN-003. Available from: http://www. mtnstopshiv.org/node/1087 [Cited 15 November 2011]
90. ClinicalTrials.gov. MTN 015: Observational Study of HIV Infected Women Previously Enrolled in Other Microbicide Trials. Available from: http://clinicaltrials.gov/ct2/show/NCT00514098?term=mtn015&rank=1 [Cited 15 November 2011]
91. ClinicalTrials.gov. MTN 016: Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure (EMBRACE). Available from: http://clinicaltrials.gov/ct2/show/NCT01209754?term=mtn016&rank=1 [Cited 15 November 2011]
92. ClinicalTrials.gov. Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression (TOAST). Available from: http://clinicaltrials.gov/ct2/show/NCT01387022?term=CAPRISA+009 &rank=1 [Cited 24 November 2011]
93. Centers for Diseases Control and Prevention. CDC Trial and another major study find PrEP can reduce risk of HIV infection among heterosexuals. CDC Press release. 2011. Available from: http://www.cdc.gov/nchhstp/newsroom/ PrEPHeterosexuals.html [Cited 13 July 2011]
94. FHI. FHI Statement on the FEM-PrEP HIV Prevention Study. 2011. Available from: http://minilicious.wordpress.com/2011/04/18/fhi-statement-on-the-femprep- hiv-prevention-study/[Cited 18 April 2011]
95. WHO/UNAIDS. Next Steps with 1% Tenofovir Gel. Meeting Report; 25-26 August 2010; Johannesburg, South Africa; 2010
96. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505
97. Williams BG, Abdool Karim SS, Gouws E, Abdool Karim Q, Potential impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 2011;58:207-10.
98. Andrei G, Lisco A, Vanpouille C, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex Virus-2 replication. Cell Host Microbes 2011;10(4):379-89
99. Vermund SH, Van Damme L. HIV prevention in women: next steps. Science 2011;331(6015):284.
100. Microbicide Trials Network. Microbicide Trials Network Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women. Available from: http://www.mtnstopshiv.org/node/3619 [Cited 1 November 2011]
101. Ware NC, Wyatt MA, Haberer JE, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples. J Acquir Immune Defic Syndr 2012; [Epub ahead of print]
102. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011;60(3):65-8
103. Hurt CB, Eron JJ Jr, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011;53(12):1265-70